PLaN Therapeutics has secured an exclusive license to advance allele-specific siRNA sequences into a therapy for PLN-R14del genetic cardiomyopathy, marking a key milestone toward clinical development for this currently untreatable disease.
Amsterdam, the Netherlands – January 22, 2026 – PLaN Therapeutics, a nonprofit biotechnology company fully owned by the PLN Foundation, today announced that they gave entered into an exclusive license agreement for a small interfering RNA (siRNA) therapy for PLN-R14del cardiomyopathy. Under the agreement, PLaN secures an exclusive option to advance siRNA sequences, developed in a collaboration between the company and Prof. Ioannis Karakikes – into a therapy for PLN-R14del genetic cardiomyopathy.
PLaN Therapeutics will work further with RNAi experts to select a lead siRNA candidate for clinical development of an allele-specific siRNA for the treatment of the PLN-R14del genetic cardiomyopathy. “Obtaining an exclusive license for this technology is critical step towards the development of a treatment for a currently untreatable disease as PLN-R14del cardiomyopathy”, said Pavlina Konstantinova, CEO of PLaN Therapeutics. “It provides hope where there currently is none.”
PLaN Therapeutics was founded with the mission to translate scientific discoveries into tangible therapies for patients affected by PLN-R14del cardiomyopathy and provide it at a fair price. The exclusive license represents a key milestone in advancing the company’s lead program from early research towards translation in the clinic.
PLN-R14del genetic cardiomyopathy, a Dutch orphan disease
PLN-R14del cardiomyopathy is caused by dominantly inherited mutation in the phospholamban (PLN) gene, resulting in a protein missing the 14th arginine. Carriers of the mutation suffer from progressive heart failure and life-threatening arrhythmias. Currently, the disease is treated with general heart failure medication, which has no effect on disease progression. Development of symptoms always results in end-stage heart failure, for which the only treatment is a heart transplant. PLaN Therapeutics is pursuing an allele-specific siRNA approach, designed to selectively silence the PLN-R14del gene without interfering with the expression wild-type gene.
About PLaN Therapeutics
PLaN Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for PLN-R14del cardiomyopathy. Originating from the PLN Foundation, the company focuses on translating cutting-edge science into treatments that address the root cause of this inherited heart disease.